Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

FRLN

Freeline Therapeutics (FRLN)

Freeline Therapeutics Holdings PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FRLN
DateTimeSourceHeadlineSymbolCompany
04/24/20244:00PMGlobeNewswire Inc.Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/26/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/22/20244:38PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/22/20244:36PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/22/20244:33PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/22/20244:32PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/22/20244:28PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/20/20243:22PMEdgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/20/20247:13AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/20/20247:00AMGlobeNewswire Inc.Acquisition of Freeline by Syncona Becomes EffectiveNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/12/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/12/202412:00PMGlobeNewswire Inc.Freeline Shareholders Approve Acquisition by SynconaNASDAQ:FRLNFreeline Therapeutics Holdings PLC
01/18/20244:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
01/17/20244:17PMEdgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/08/20235:21PMEdgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/01/20238:56AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
11/22/20239:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
11/22/20237:30AMGlobeNewswire Inc.Syncona to Acquire Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/25/20236:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/25/20232:01AMGlobeNewswire Inc.Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/18/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/16/20237:00AMGlobeNewswire Inc.Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/06/20234:52PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/04/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
10/04/20237:00AMGlobeNewswire Inc.Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/15/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/15/20237:00AMGlobeNewswire Inc.Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/08/20237:30AMGlobeNewswire Inc.Freeline Therapeutics to Host Second Quarter 2023 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
07/31/20237:30AMGlobeNewswire Inc.Freeline to Participate in Upcoming Investor ConferencesNASDAQ:FRLNFreeline Therapeutics Holdings PLC
07/25/20237:30AMGlobeNewswire Inc.Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:FRLN